Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer.
Mikael AnttinenPietari MäkeläPertti NurminenEemil Yli-PietiläVisa SuomiTeija SainioJani SaunavaaraPekka TaimenRoberto Blanco SequeirosPeter J BoströmPublished in: Scandinavian journal of urology (2020)
pTULSA appears safe and feasible for palliative ablation of locally advanced prostate cancer. The therapy seems to accomplish long-term hematuria control, can relieve bladder outlet obstruction in selected patients, and seems to reduce the burden of hospitalization due to local complications. Trial Registration Number: NCT03350529.
Keyphrases
- prostate cancer
- locally advanced
- rectal cancer
- squamous cell carcinoma
- radical prostatectomy
- neoadjuvant chemotherapy
- end stage renal disease
- magnetic resonance imaging
- palliative care
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- radiation therapy
- phase ii study
- study protocol
- risk factors
- advanced cancer
- spinal cord injury
- prognostic factors
- computed tomography
- randomized controlled trial
- stem cells
- radiofrequency ablation
- phase iii
- contrast enhanced
- bone marrow
- phase ii
- catheter ablation
- diffusion weighted imaging
- ultrasound guided